Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia  by Nakamura, Yoichi et al.
ORIGINAL ARTICLE
Randomized Phase II Trial of Irinotecan with Paclitaxel or
Gemcitabine for Non-small Cell Lung Cancer
Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia
Yoichi Nakamura, MD, PhD,* Hiroshi Soda, MD, PhD,† Mikio Oka, MD, PhD,‡
Akitoshi Kinoshita, MD, PhD,§ Minoru Fukuda, MD, PhD, Masaaki Fukuda, MD, PhD,¶
Hiroshi Takatani, MD, PhD,¶ Seiji Nagashima, MD,† Yoshifumi Soejima, MD, PhD,#
Takashi Kasai, MD, PhD,¶ Katsumi Nakatomi, MD, PhD,* Noriyuki Masuda, MD, PhD,**
Kazuhiro Tsukamoto, MD, PhD,†† and Shigeru Kohno, MD, PhD*
Hypothesis: Irinotecan-containing regimens are known to be active
and tolerable in patients with non-small cell lung cancer (NSCLC).
A randomized phase II trial was conducted to evaluate the efficacy
of irinotecan plus paclitaxel or gemcitabine for previously untreated
stage IIIB or stage IV NSCLC.
Patients and Methods: Previously untreated patients with adequate
organ function who gave written informed consent were randomly
assigned to receive irinotecan (50 mg/m2 on days 1, 8, and 15) plus
paclitaxel (180 mg/m2 on day 1) every 4 weeks (IP group) or
irinotecan (100 mg/m2 on days 1 and 8) plus gemcitabine (1000
mg/m2 on days 1 and 8) every 3 weeks (IG group). The primary
endpoint was the response rate. We also evaluated the relationship of
response and toxicity to polymorphisms of the uridine diphosphate
glucuronosyltransferase (UGT) gene.
Results: Eighty patients were enrolled, and 78 patients were eligible
(38 in the IP group and 40 in the IG group). The response rate was
31.6% (95% confidence interval: 17.5–48.7%) in the IP group and
20.0% (9.1–35.6%) in the IG group. The median progression-free
survival time was 86 days and 145 days, respectively. Both regimens
were well tolerated. The most common severe adverse event was
grade 4 neutropenia (36.8% and 10.0%, respectively), which was
associated with UGT1A1*6 and UGT1A1*27. UGT polymorphisms
did not correlate with response.
Conclusions: Irinotecan plus paclitaxel may be more active against
NSCLC than irinotecan plus gemcitabine. The UGT1A1*6 and
UGT1A1*27 genotypes might be useful predictors of grade 4 neu-
tropenia in patients who receive irinotecan-based chemotherapy.
Key Words: NSCLC, Irinotecan, Paclitaxel, Gemcitabine,
UGT1A1*6, UGT1A1*27.
(J Thorac Oncol. 2011;6: 121–127)
Non-small cell lung cancer (NSCLC) accounts for approx-imately 80% of all cases of lung cancer and remains the
leading cause of cancer-related death in many countries.1
Several third-generation agents are available for the treatment
of advanced NSCLC. One of these agents combined with
cisplatin or carboplatin has been considered standard therapy
for previously untreated advanced NSCLC.2
Nevertheless, approximately one third of all patients
with advanced NSCLC do not clinically benefit from plati-
num-based chemotherapy,2 and nonplatinum regimens show
equivalent efficacy with a different toxicity profile.3 Recent
studies have reported that biologic factors such as expression
of excision repair cross-complementation group 1 mRNA
confer resistance of NSCLC to platinum agents.4 This finding
suggests that nonplatinum regimens might be preferable in
certain patients with biologic markers of platinum resistance.
Irinotecan is a semisynthetic derivative of camptoth-
ecin. The active metabolite of irinotecan (SN-38) inhibits
topoisomerase-I activity by stabilizing the topoisomerase
I-DNA cleavable complex.5 Paclitaxel is an antimicrotubule
agent that produces antitumor activity by promoting tubulin
polymerization and stabilization of microtubules against de-
polymerization. Gemcitabine is an analog of the pyrimidine
antimetabolite cytarabine, which produces antitumor activity
by targeting the S phase of the cell cycle.6 These three drugs
have different mechanisms of action, and their toxicity pro-
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files do not overlap. Two phase I studies have assessed the
combination of irinotecan and paclitaxel (IP) or irinotecan
and gemcitabine (IG), and both regimens showed relatively
good safety and efficacy as first-line treatment for advanced
NSCLC.7,8 Therefore, we conducted a randomized phase II
study to determine which irinotecan-based regimen (IP or IG)
is superior for use in a future large-scale trial.
It is well known that uridine diphosphate glucuronosyl-
transferase (UGT) gene polymorphisms affect the activity of
key enzymes involved in irinotecan metabolism.9–16 We also
examined the association of polymorphisms of the UGT1A1
(*6, *27, *28, and *60), UGT1A7 (*2, *3, and *4), and
UGT1A9 (*22) genes with the outcomes of IP and IG therapy.
PATIENTS AND METHODS
Eligibility Criteria
Eligibility criteria were as follows: histologically or
cytologically confirmed stage IIIB/IV NSCLC; no prior treat-
ment; measurable and eligible disease; age between 20 and 75
years; Eastern Cooperative Oncology Group performance
status of 0 or 1; adequate bone marrow function; adequate
liver function; and serum creatinine below the upper limit of
normal. The exclusion criteria were superior vena cava syn-
drome, massive pleural effusion or ascites, symptomatic cen-
tral nervous system metastasis, concomitant active malig-
nancy, clinically significant cardiac disease, infection, watery
diarrhea, paralytic ileus, and intestinal obstruction. Pregnant
or breast-feeding women were also excluded. Written in-
formed consent was obtained from all patients before treat-
ment. The study protocol and the informed consent proce-
dures were reviewed and approved by the institutional review
board of each participating hospital.
Treatment Schedule
This was an open-labeled, randomized phase II trial.
Eligible patients were registered with the data center and
randomized to receive IP therapy (IP group) or IG therapy
(IG group) by centralized dynamic allocation. The stratifica-
tion factors used were performance status (0/1), stage (IIIB/
IV), and institution.
In the IP group, irinotecan was given at a dose of 50
mg/m2 on days 1, 8, and 15. Paclitaxel was given at a dose
of 180 mg/m2 on day 1 only. Premedication was adminis-
tered 30 minutes before the paclitaxel infusion. This cycle
was repeated every 4 weeks. Patients enrolled in the IG
group received irinotecan at 100 mg/m2 and gemcitabine at
1000 mg/m2 on days 1 and 8. This cycle was repeated
every 3 weeks.
The treatment scheduled for days 8 and 15 or the start
of the next cycle was delayed if the patient had a leukocyte
count of less than 3000 or more than 12,000/mm3, a platelet
count of less than 100,000/mm3, diarrhea ofgrade 1, and/or
other nonhematologic toxicities of grade 3 (except electro-
lyte abnormality, nausea, anorexia, and fatigue). If these toxic
effects did not resolve sufficiently, the doses scheduled for
days 8 and/or 15 were omitted. The patient was withdrawn
from the study if the next cycle of therapy could not be started
within 4 weeks from the previously administered dose. The
treatment goal was for patients to receive at least three cycles
in the IP group and four cycles in the IG group. Treatment
was continued until there was evidence of disease progres-
sion, intolerable toxicity, or patient refusal. As for dose
modification, if there was grade 4 neutropenia for 5 days,
thrombocytopenia of grades 3 to 4, or nonhematologic tox-
icity of grades 3 to 4 (except electrolyte abnormality, nausea,
anorexia, and fatigue), then the dose of paclitaxel in the IP
group or irinotecan in the IG group was reduced to 150
mg/m2 and 80 mg/m2, respectively. If grades 3 to 4 diarrhea
occurred, only irinotecan was reduced to 80% of the previous
dose in both arms.
Before enrollment, a complete medical history was
obtained, and physical examination was performed. In addi-
tion, a complete blood count, biochemistry tests, blood gas
analysis, chest roentgenography, electrocardiography, com-
puted tomography (CT) of the brain and chest, CT of the
abdomen, and bone scintigraphy were performed. Patients
were monitored at weekly intervals throughout treatment by
physical examination, recording of toxicities, complete blood
counts, and biochemistry tests.
The response was assessed at least every two cycles
according to the RECIST (version 1.0).17 Toxicity was as-
sessed according to the National Cancer Institute Common
Toxicity Criteria, version 2.0.18 Extramural reviewers were
used to determine the eligibility, assessability, and response
of each patient.
Genotype Analysis
DNA samples were extracted from peripheral blood,
and genomic DNA was isolated from 77 patients who
provided informed consent, using a DNA Purification Kit
(QIAGEN Japan, Tokyo, Japan). Then, polymerase chain
reaction (PCR) was done for amplification, and the PCR-
direct DNA sequencing method was used to analyze the
genotypes of UGT1A1*6, UGT1A1*27, UGT1A7, and
UGT1A9*22. In addition, UGT1A1*28 was analyzed by poly-
acrylamide gel electrophoresis, and UGT1A1*60 was ana-
lyzed by TaqMan PCR. In this trial, we considered both IP
and IG to be the low-dose weekly irinotecan regimens, and
we evaluated the relationship between UGT genotype and
toxicities in both treatment groups combined.
Statistical Analysis
The full analysis set was defined as all patients who
received treatment at least once and met all the inclusion
criteria. The per-protocol set was defined as all patients who
received treatment at least once and had no major protocol
violations.
The primary endpoint of this study was the overall
response rate (ORR). The secondary endpoints were progres-
sion-free survival (PFS), overall survival, 1-year survival,
2-year survival, and toxicities. Assuming that the ORR would
be 30% in the IP group and 45% in the IG group, we
estimated that 35 patients per arm were required to give the
study a power of 0.90 to detect a difference in response
between the groups.19 Thus, the target sample size was set as
80 patients (40/group). PFS was defined as the time from the
date of registration to the date of disease progression or death,
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and overall survival was defined as the time from the date of
registration to the date of death. Survival was estimated by
the Kaplan-Meier method. As an exploratory analysis, the
association of UGT1A genotypes with toxicity or tumor
response was assessed by Wald’s test. All analyses were
performed with SAS software (version 8.2; SAS Institute,
Cary, NC).
The genotype frequencies for each single-nucleotide
polymorphism were analyzed in an exploratory fashion to
assess consistency between the observed values and those ex-
pected from Hardy–Weinberg equilibrium, using Haploview
version 3.32. Haploview based on the expectation-maximization
method20 was used to estimate haplotype frequencies, Le-
wontin’s coefficients (D),21 and correlation coefficients (r2).22
The block structures and their haplotype frequencies were esti-
mated using Haploview version 3.32.
This trial was registered with the Japan Pharmaceutical
Information Center (JapicCTI-050111).
RESULTS
Patient Characteristics
From January 2004 to April 2006, 80 patients were
enrolled (40 in the IP group and 40 in the IG group). Two
patients were not eligible (both in the IP group), because one
had received surgery for a brain metastasis and the other had
interstitial fibrosis of the lungs. Table 1 lists the baseline
characteristics of the 78 eligible patients. The median number
of treatment cycles was three in the IP group (range: 1–6
cycles) and four in the IG group (range: 1–9 cycles). The
relative dose intensity was 100% for paclitaxel and 66.7% for
irinotecan in the IP group (n  38), and 95.1% for gemcit-
abine and 94.0% for irinotecan in the IG group (n  40). The
most common reason for stopping treatment was disease
progression (52.6% in the IP group and 25.0% in the IG
group). After this study, 89.7% of the patients received
subsequent chemotherapy (36 patients in the IP group and 34
patients in the IG group). Cross-over administration was not
performed in any patient.
Toxicity
Adverse events are listed in Table 2. Neutropenia of
grades 3 and 4 was comparable in the IP and IG groups, but
grade 4 neutropenia occurred in 36.8% of the patients in
the IP group versus only 10.0% of those in the IG group.
Grade 3 diarrhea and constipation were observed in 7.9%
and 10.5% of patients in the IP group versus 5.0% and
5.0% of those in the IG group, respectively. All the adverse
events were tolerable, and there were no treatment-related
deaths.
Response and Survival
In the IP group, there were 12 partial responses (PRs)
for an ORR of 31.6% (95% confidence interval [CI]: 17.5–
48.7%). In addition, 13 patients (34.2%) had stable disease
(SD), and 12 patients (31.6%) had progressive disease. In the
IG group, there were eight PRs for an ORR of 20.0% (95%
CI: 9.1–35.6%). There were 25 patients (65.8%) with SD and
six patients (15.8%) with progressive disease. One patient
could not be assessed in each group. Median PFS was 86 days
(95% CI: 78–138 days) in the IP group and 145 days (95%
CI: 109–145 days) in the IG group (Figure 1A). The median
survival time, 1-year survival rate, and 2-year survival rate
were 439 days (95% CI: 357–608 days), 62.9% (95% CI:
47.4–78.3%), and 27.3% (95% CI: 12.9–41.7%) in the IP
group versus 540 days (95% CI: 337–670 days), 64.7% (95%
CI: 49.7–79.6%), and 32.4% (95% CI: 17.5–47.4%) in the IG
group, respectively (Figure 1B).
TABLE 2. Toxicities
No. of Patients
G0 G1 G2 G3 G4 >G3 (%)
Leukopenia
IP group 3 9 15 10 1 28.9
IG group 5 5 21 9 0 22.5
Neutropenia
IP group 2 4 2 16 14 78.9
IG group 5 2 13 16 4 50.0
Febrile neutropenia
IP group 33 0 3 2 0 5.3
IG group 28 5 3 4 0 10.0
Diarrhea
IP group 22 10 3 3 0 7.9
IG group 19 13 6 2 0 5.0
Constipation
IP group 26 2 6 4 0 10.5
IG group 21 7 10 2 0 5.0
Neruopathy
IP group 13 22 3 0 0 0
IG group 39 1 0 0 0 0
Pneumonitis
IP group 37 0 1 0 0 0
IG group 35 2 3 0 0 0
G, grade; IP, irinotecan and paclitaxel; IG, irinotecan and gemcitabine.
TABLE 1. Patient Characteristics
IP Group
(Irinotecan/
Paclitaxel)
IG Group
(Irinotecan/
Gemcitabine)
No. of patients evaluated 38 40
Male/female 26/12 28/12
Age
65 yr 20 24
65 yr 18 16
Stage IIIB/IV 7/31 8/32
PS 0/1 10/28 11/29
Histology
Adenocarcinoma 30 31
Squamous 7 6
Others 1 3
IP, irinotecan and paclitaxel; IG, irinotecan and gemcitabine.
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Association of UGT1A Genotype with Study
Outcomes
The frequencies of UGT1A haplotypes and genotypes
are listed in Table 3. No Hardy-Weinberg disequilibrium was
observed (p  0.05). We constructed haplotypes using six
polymorphisms (UGT1A9*22, UGT1A7*, UGT1A1*60,
UGT1A1*28, UGT1A1*6, and UGT1A1*27) to examine the
effects of these key single-nucleotide polymorphisms and
found 10 haplotypes. The three most common haplotypes
accounted for 78.3% of all haplotypes. This result was in
agreement with findings previously reported for Asian pa-
tients.15 The variants of UGT1A1, UGT1A7, and UGT1A9
typed in this study are listed in Table 3. There were no
patients homozygous for UGT1A1*27, and all the patients
FIGURE 1. Kaplan-Meier curves for (A) progression-free survival and (B) overall survival.
TABLE 3. Frequency of UGT1A Haplotypes and Genotypes
Haplotype
UGT1A9*22,
-118(T)10>(T)9
UGT1A7(*),a 387T>G,
391C>A, 392G>A,
622T>C
UGT1A1*60,
-3279 T>G
UGT1A1*28,
-53(TA)6>7
UGT1A1*6,
211G>A
UGT1A1*27,
686C>A
Frequency
(%)
1 10 TCGT(*1) T 6 G C 57.0
2 9 GAAC(*3) T 6 A C 10.6
3 9 GAAT(*2) G 6 G C 10.7
4 10 TCGT(*1) G 7 G C 7.6
5 9 GAAC(*3) T 6 G C 4.3
6 10 TCGT(*1) T 6 A C 1.4
7 9 GAAC(*3) G 7 G C 4.4
8 9 GAAT(*2) G 7 G C 0.7
9 10 GAAC(*3) T 6 A C 0.7
10 9 GAAT(*2) G 7 G A 2.7
UGT1A Genotype Wild Type Hetero Homo NA
UGT1A1*28 6/6 6/7 7/7 —
n 58 16 3 0
UGT1A1*6 G/G G/A A/A —
n 58 17 2 0
UGT1A1*27 C/C C/A A/A —
n 73 4 0 0
UGT1A1*60 T/T T/G G/G —
n 43 22 8 4
UGT1A7 (*1,*2,*3,*4) *1/*1, *1/*2, *1/*3 *2/*3 *2/2, *3/3 —
n 64 6 3 4
UGT1A9*22 10/10 10/9 9/9 —
N 34 30 9 4
a UGT1A7*1: TCGT; UGT1A7*2: GAAT; UGT1A7*3: GAAC; and UGT1A7*4: TCGC.
NA, not analyzed; hetero, heterozygous; homo, homozygous.
Nakamura et al. Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer124
heterozygous for UGT1A1*27 were also heterozygous for
UGT1A1*28. These results were also consistent with data
previously reported for Asian patients.9,14–16
High linkage disequilibrium was observed among
UGT1A7 variants with D values of 1 and r2 values ranging
from 0.485 to 1, which included 387TG, 391CA,
392GA, and 622TC (Figure 2). We found a linkage
association (0.444  r2  0.971; 0.942  D  1) between
UGT1A7 variants and UGT1A9*22. UGT1A7 (622TC) and
UGT1A1*6 were also in high linkage disequilibrium (D  0.
854, r2  0.423). On the other hand, a close association was
not observed between UGT1A1*28 and UGT1A7. We found
a close linkage across UGT1A1*28 and UGT1A1*60 (D  1,
r2  0.52). There was no UGT1A7*4 in this study. Our
results were similar to those of a study by Han et al.15
We examined the association of UGT1A genotypes
with the toxicity profile in 77 eligible patients (one patient
refused genotyping). Patients who were homozygous or het-
erozygous for UGT1A1*6 and UGT1A1*27 had a higher
incidence of grade 4 neutropenia (p  0.020 and 0.033,
respectively) (Table 4). In contrast, the other UGT1A geno-
types were not significantly associated with neutropenia.
None of the UGT1A genotypes analyzed in this study had a
significant association with grade 3 diarrhea. Although ho-
mozygosity for UGT1A1*28, previously reported as showing
the most significant association with irinotecan-related toxic-
ity, was found in three patients, it was not associated with any
adverse events during this trial.9,11 There were no significant
differences in response, survival, or the delivered dose of
irinotecan according to UGT1A genotype.
DISCUSSION
This randomized study showed that the IP group
achieved a higher response rate than the IG group (31.6%
versus 20.0%, respectively). Although our sample size was
small, the other efficacy data obtained in the IP group were
comparable with the results for platinum-based regimens
containing irinotecan or other third-generation anticancer
drugs.2 The paclitaxel dose used in this study (180 mg/m2)
was lower than that reported for other paclitaxel-containing
regimens, but this dose was based on the results of a previous
phase I study in chemotherapy-naive Japanese patients.7
Thus, patients in the IP group were considered to have
received appropriate paclitaxel doses.
This study showed that the IP and IG regiments were
both well tolerated by patients with advanced NSCLC. The
median numbers of treatment cycles administered in the IP
and IG groups was three and four, respectively, which were
consistent with the study design. Nevertheless, the delivered
dose of irinotecan was lower in the IP group (dose intensity:
66.7%) because doses were skipped on days 8 and 15 (espe-
cially because of leukopenia). Although this was not a major
problem in phase I trials, an increase in the deliverable dose
of irinotecan in IP group may require modification of the
timing for the administration of irinotecan in IP regimens,
such as skipping treatment on day 8 or 15.
Recently, excision repair cross-complementation 1
(ERCC1) has been recognized as an invaluable biomarker for
prediction of the clinical response to cisplatin-based chemo-
therapy in patients with NSCLC. Olaussen et al.4 have re-
ported that patients with ERCC1-negative tumors seem to
benefit from adjuvant cisplatin-based chemotherapy, whereas
those with ERCC1-positive tumors do not. A meta-analysis
by Chen et al.23 has also shown that low or negative expres-
FIGURE 2. Linkage disequilibrium analysis for UGT1A1, UGT1A7, and UGT1A9 single-nucleotide polymorphisms. D (upper,
red) and r2 (lower, blue) values are shown for each square.
TABLE 4. UGT Genotypes and Neutropenia
Grade 4/All Percentage OR p
UGT1A1*28
Wild type 12/58 20.7 1.369 0.609
Hetero/homo 5/19 26.3
UGT1A1*6
Wild type 9/58 15.5 3.960 0.020
Hetero/homo 8/19 42.1
UGT1A1*27
Wild type 14/73 19.2 12.643 0.033
Hetero/homo 3/4 75.0
UGT1A1*60
Wild type 8/43 18.6 1.591 0.415
Hetero/homo 8/30 26.7
UGT1A7
Wild type 12/64 18.8 3.467 0.094
Hetero/homo 4/9 44.4
UGT1A9*22
Wild type 4/34 11.8 3.333 0.058
Hetero/homo 12/39 30.8
Hetero/homo, heterozygous/homozygous.
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sion of ERCC1 is associated with a better objective response
and longer median survival in patients with advanced NSCLC
who receive platinum-based chemotherapy. In that meta-
analysis, patients with high/positive expression of ERCC1
who received platinum-based chemotherapy had an overall
objective response rate of 28.4%. In this study, the ORR in
the IP group was 31.6%, suggesting that IP might be more
effective for the patients with ERCC1-positive NSCLC. Nev-
ertheless, this must be confirmed in future clinical trials.
The ORR in the IP group was superior to that in the IG
group, whereas PFS in the IP group was inferior to that in the
IG group. A recent meta-analysis assessing the antitumor
activities of third-generation drugs for the first-line treatment
of advanced NSCLC reported that paclitaxel-based regimens
are associated with a significantly higher risk of earlier
progression, despite having a response rate comparable to
that of other third-generation regimens.24 This finding is in
accord with the results of our study. Although the primary
endpoint in our study design was ORR, the reasons for the
discrepancy between ORR and PFS remain unknown. More-
over, Watanabe et al.25 showed in their meta-analysis that the
disease control rate (CR, PR, and SD) is a more sensitive
predictor of outcomes than the response rate (CR and PR) in
patients with advanced NSCLC treated with platinum-based
chemotherapy. The disease control rate in the IP group and
IG group was 67.7% and 84.6%, respectively. Further studies
are required to clarify whether the optimal primary endpoint
of a phase II study is the response rate or disease control rate.
In this study, five patients had grade 1 or 2 pneumonitis
in the IG group. All cases of pneumonitis were mild and
controllable; however, the incidence was rather high. Re-
cently, new molecular targeted drugs such as cetuximab or
bevacizumab have been used in combination with cytotoxic
drug regimens to treat advanced NSCLC. Regimens includ-
ing molecular targeted drugs have been associated with a
higher incidence of pneumonitis than combined treatment
with cytotoxic drugs alone.26 IP may be better suited for
combined therapy with molecular targeted drugs because it
has a low frequency of pneumonitis, a serious and potentially
fatal toxic effect. IP might a better candidate for future
clinical trials than nonplatinum regimens in advanced
NSCLC with low or negative expression of ERCC1.
UGT1A genotype analysis revealed that there was no
relationship between UGT polymorphisms and response;
however, grade 4 neutropenia was significantly associated
with UGT1A1*6 and *27 but not with *28. In general,
patients with UGT1A1*27 also harbor UGT1A1*28, whereas
those with UGT1A1*28 do not necessarily harbor
UGT1A1*27.27 Both UGT1A1*6 and *27 have only been
identified in Asians, and UGT1A1*6 has been reported to be
associated with irinotecan-induced toxicities.28,29 On the
other hand, UGT1A1*27 is a rare polymorphism, and it
remains unclear whether it is associated with irinotecan
toxicity. Ando et al.9 reported that only three patients were
heterozygous for UGT1A1*27, and all of them had severe
neutropenia and/or diarrhea. To the best of our knowledge,
this is the first study that has demonstrated a significant
association between UGT1A1*27 polymorphism and neutro-
penia due to irinotecan-containing regimens. Hoskins et al.30
revealed that the risk of hematological toxicities among
patients with a UGT1A1*28 genotype did not significantly
differ from that among patients with wild-type alleles in the
subgroup of patients treated with low-dose weekly irinotecan
(100 mg/m2). Thus, evaluation of UGT1A1*27 genotype
rather than UGT1A1*28 genotype may enhance the ability to
predict toxicities in the clinical setting of low-dose weekly
irinotecan chemotherapy.
In conclusion, the response rate achieved in the IP
group was higher than that in the IG group, whereas the
toxicities of both regimens were controllable. The
UGT1A1*6 and *27 genotypes might be useful for predicting
grade 4 neutropenia due to low-dose weekly irinotecan reg-
imens. To confirm the findings of this study, further prospec-
tive studies are needed in an independent data set.
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